Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Corcept Therapeutics (CORT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,455,267
  • Shares Outstanding, K 116,050
  • Annual Sales, $ 159,200 K
  • Annual Income, $ 129,120 K
  • 36-Month Beta 1.62
  • Price/Sales 9.14
  • Price/Cash Flow 27.24
  • Price/Book 5.93

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 0.16
  • Number of Estimates 2
  • High Estimate 0.18
  • Low Estimate 0.13
  • Prior Year 0.11
  • Growth Rate Est. (year over year) +45.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.09 +0.66%
on 10/19/18
14.78 -17.66%
on 10/03/18
-2.05 (-14.42%)
since 09/19/18
3-Month
11.55 +5.37%
on 08/10/18
15.11 -19.46%
on 08/31/18
-1.05 (-7.94%)
since 07/19/18
52-Week
11.55 +5.37%
on 08/10/18
25.96 -53.12%
on 01/29/18
-6.13 (-33.50%)
since 10/19/17

Most Recent Stories

More News
Do Options Traders Know Something About Corcept (CORT) Stock We Don't?

Investors need to pay close attention to Corcept (CORT) stock based on the movements in the options market lately.

CORT : 12.17 (-2.95%)
Cushing's Syndrome Diagnostic & Treatment Market (2018-2023) Featuring Novartis, Corcept Therapeutics, StrongBridge Biopharma, Orphagen Pharma, and HRA Pharma - ResearchAndMarkets.com

The "Cushing's Syndrome Diagnostic and Treatment Market - Forecasts from 2018 to 2023" report has been added to ResearchAndMarkets.com's offering.

CORT : 12.17 (-2.95%)
NVS : 87.19 (+1.10%)
SBBP : 4.87 (-1.02%)
Analysis: Positioning to Benefit within ShotSpotter, Frank's International N.V., Taseko Mines, Office Depot, Rudolph Technologies, and Corcept Therapeutics -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ShotSpotter Inc. (NASDAQ:SSTI),...

CORT : 12.17 (-2.95%)
SSTI : 40.00 (-2.96%)
FI : 7.73 (-1.40%)
RTEC : 19.91 (-2.83%)
ODP : 2.65 (-4.68%)
TGB : 0.71 (+2.90%)
Corcept (CORT) Earnings and Revenues Miss Estimates in Q2

Corcept's (CORT) earnings and revenues lag estimates in Q2. Meanwhile, the company posts positive interim data from phase I/II study on its pipeline candidate relacorilant.

CORT : 12.17 (-2.95%)
CELG : 82.41 (-0.65%)
ILMN : 313.10 (-2.60%)
PFE : 44.50 (+1.14%)
Corcept Therapeutics (CORT) Misses Q2 Earnings and Revenue Estimates

Corcept (CORT) delivered earnings and revenue surprises of -16.67% and -9.08%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

CORT : 12.17 (-2.95%)
Corcept: 2Q Earnings Snapshot

MENLO PARK, Calif. (AP) _ Corcept Therapeutics Inc. (CORT) on Thursday reported second-quarter net income of $18.2 million.

CORT : 12.17 (-2.95%)
Corcept Therapeutics Incorporated. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Corcept Therapeutics Incorporated. (NASDAQ: ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 5:00 PM Eastern...

CORT : 12.17 (-2.95%)
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on August 9, 2018. The Company will also host a conference...

CORT : 12.17 (-2.95%)
Corcept Therapeutics Becomes Oversold (CORT)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...

CORT : 12.17 (-2.95%)
Market Trends Toward New Normal in Agios Pharmaceuticals, Corcept Therapeutics, Prestige Brand, Virtu Financial, Eagle Pharmaceuticals, and Century Aluminum -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Agios Pharmaceuticals, Inc....

CORT : 12.17 (-2.95%)
AGIO : 66.88 (+0.09%)
CENX : 9.80 (-1.21%)
PBH : 37.57 (-0.92%)
EGRX : 58.08 (-2.37%)
VIRT : 22.75 (+1.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade CORT with:

Business Summary

Corcept Therapeutics Incorporated is a pharmaceutical company. It is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The company focuses on disorders that are associated with a steroid hormone called cortisol....

See More

Key Turning Points

2nd Resistance Point 12.80
1st Resistance Point 12.48
Last Price 12.17
1st Support Level 11.97
2nd Support Level 11.78

See More

52-Week High 25.96
Fibonacci 61.8% 20.46
Fibonacci 50% 18.75
Fibonacci 38.2% 17.05
Last Price 12.17
52-Week Low 11.55

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar